Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 16/20 | 0.43 |
| ▸ | HTR1A | P08908 | 14/20 | 0.43 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | HTR6 | P50406 | 5/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14020191 | 0.93 | CDK4 (0.40) | HTR7HTR1ADRD2HTR6CDK4 | |
| SCHEMBL14020216 | 0.88 | HTR1A (0.46) | HTR7HTR1ADRD2HTR6CDK2 | |
| SCHEMBL14020187 | 0.87 | HTR2A (0.40) | HTR7HTR1ADRD2CDK4CCNE1 | |
| SCHEMBL14020190 | 0.85 | CDK2 (0.38) | HTR7HTR1ADRD2CDK4CCNE1 | |
| SCHEMBL14020201 | 0.84 | CDK2 (0.38) | HTR7HTR1ADRD2CDK4CCNE1 | |
| SCHEMBL3302160 | 0.82 | IKBKB (0.47) | CDK4CCNE1CDK2IKBKBCHUK | |
| SCHEMBL14020208 | 0.81 | CDK2 (0.39) | HTR7HTR1ADRD2CDK4CCNE1 | |
| SCHEMBL14020197 | 0.79 | HTR2A (0.47) | HTR7HTR1ADRD2CDK2HTR2A | |
| SCHEMBL13392087 | 0.78 | IKBKB (0.46) | CDK4CCNE1CDK2IKBKBCHUK | |
| SCHEMBL14020199 | 0.78 | DRD2 (0.40) | HTR7HTR1ADRD2CDK4CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | HTR7 3944/4885HTR1A 3698/4885DRD2 2869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.